CoChat
Sign Up
Cited by 7Cervical Cancer and HPV ResearchWomen's cancer prevention and managementReproductive tract infections research

Utility of Human Papillomavirus Testing for Cervical Cancer Screening in Korea.

Open access
Kim, Mee-seon, Lee, Eun Hee, Park, Moon-il, Lee, Jae Seok, Kim, Kisu, Roh, Mee Sook, Lee, Hyoun Wook·2020·International Journal of Environmental Research and Public Health
DOI 10.3390/ijerph17051726PMC PMC7084278
Open this paper in CoChat — free accountOpen PDF

Abstract

(1) Background: Cervical cancer is one of the most common cancers in Korean women. This study was performed to discover the utility of HPV (Human Papillomavirus) testing in screening of cervical lesions and to provide the prevalence of HPV and the genotype distribution in a single center of Korea. (2) Methods: A total of 15,141 women who underwent both HPV testing and cervical cytology were enrolled in this retrospective medical record review study. (3) Results: HPV testing showed higher sensitivity than cytology for the detection of histological high-grade squamous lesions. Furthermore, the sensitivity and specificity of HPV testing varied depending on the method used. The BD Onclarity™ HPV assay had higher sensitivity (90%) than the MyHPV CHIP™ kit (all types of HPV: 82%; high-risk HPV: 76%) for high-grade squamous lesions. A combination of MyHPV CHIP™ and cytology detected 90.9% (30/33) of histological high-grade squamous lesions. A combination of BD Onclarity™ HPV assay and cytology detected 96.55% (84/87) of histological high-grade squamous lesions. In addition, HPV prevalence and genotype distribution were different depending on the HPV testing method used. (4) Conclusion: HPV testing showed higher sensitivity than cytology, but the sensitivity and specificity of HPV testing had variation depending on the method used.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijerph17051726

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Onclarity is an FDA-approved HPV genotyping test widely used for cervical cancer screening, including at several major hospitals in South Korea.

    “Onclarity is an FDA-approved HPV genotyping test widely used for cervical cancer screening including several major hospitals at South Korea [29].”

    From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [29]

    Methods §2.5 identifies BD Onclarity as an HPV genotyping assay, and Methods §2.1 reports its use in cervical screening at Samsung Changwon Hospital in Korea. The paper does not establish FDA approval, widespread use, or use at several major South Korean hospitals; its study draws records from one hospital. Page numbers were not available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 24

  1. [1]Jung K.W. Won Y.J. Kong H.J. Lee E.S. Prediction of Cancer Incidence and Mortality in Korea, 2019 Cancer Res. Treat. 2019 51 431 437 10.4143/crt.2019.139 30913864 PMC6473283 · DOI
  2. [2]Jung K.W. Won Y.J. Oh C.M. Kong H.J. Lee D.H. Lee K.H. Community of Population-Based Regional Cancer Registries. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014 Cancer Res. Treat. 2017 49 292 305 10.4143/crt.2017.118 28279062 PMC5398380 · DOI
  3. [3]Zur Hausen H. Papillomaviruses and Cancer: From Basic Studies to Clinical Application Nat. Rev. Cancer 2002 2 342 350 10.1038/nrc798 12044010 · DOI
  4. [4]Reid R. Stanhope C.R. Herschman B.R. Booth E. Phibbs G.D. Smith J.P. Genital Warts and Cervical Cancer. I. Evidence of an Association between Subclinical Papillomavirus Infection and Cervical Malignancy Cancer 1982 50 377 387 10.1002/1097-0142(19820715)50:2<377::AID-CNCR2820500236>3.0.CO;2-A 6282442 · DOI
  5. [5]Walboomers J.M. Jacobs M.V. Manos M.M. Bosch F.X. Kummer J.A. Shah K.V. Snijders P.J. Peto J. Meijer C.J. Munoz N. Human Papillomavirus is a Necessary Cause of Invasive Cervical Cancer Worldwide J. Pathol. 1999 189 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 · DOI
  6. [6]Mayrand M.H. Duarte-Franco E. Rodrigues I. Walter S.D. Hanley J. Ferenczy A. Ratnam S. Coutlee F. Franco E.L. Canadian Cervical Cancer Screening Trial Study Group. Human Papillomavirus DNA Versus Papanicolaou Screening Tests for Cervical Cancer N. Engl. J. Med. 2007 357 1579 1588 10.1056/NEJMoa071430 17942871 · DOI
  7. [7]Ronco G. Dillner J. Elfstrom K.M. Tunesi S. Snijders P.J. Arbyn M. Kitchener H. Segnan N. Gilham C. Giorgi-Rossi P. Efficacy of HPV-Based Screening for Prevention of Invasive Cervical Cancer: Follow-Up of Four European Randomised Controlled Trials Lancet 2014 383 524 532 10.1016/S0140-6736(13)62218-7 24192252 · DOI · Paper page
  8. [8]Ogilvie G.S. Krajden M. van Niekerk D.J. Martin R.E. Ehlen T.G. Ceballos K. Smith L.W. Kan L. Cook D.A. Peacock S. Primary Cervical Cancer Screening with HPV Testing Compared with Liquid-Based Cytology: Results of Round 1 of a Randomised Controlled Trial-the HPV FOCAL Study Br. J. Cancer 2012 107 1917 1924 10.1038/bjc.2012.489 23169286 PMC3516684 · DOI
  9. [9]Gyllensten U. Gustavsson I. Lindell M. Wilander E. Primary High-Risk HPV Screening for Cervical Cancer in Post-Menopausal Women Gynecol. Oncol. 2012 125 343 345 10.1016/j.ygyno.2012.01.036 22293044 · DOI
  10. [10]Malila N. Leinonen M. Kotaniemi-Talonen L. Laurila P. Tarkkanen J. Hakama M. The HPV Test has Similar Sensitivity but More Overdiagnosis than the Pap Test-a Randomised Health Services Study on Cervical Cancer Screening in Finland Int. J. Cancer 2013 132 2141 2147 10.1002/ijc.27850 22987601 · DOI
  11. [11]Arbyn M. Raifu A.O. Weiderpass E. Bray F. Anttila A. Trends of Cervical Cancer Mortality in the Member States of the European Union Eur. J. Cancer 2009 45 2640 2648 10.1016/j.ejca.2009.07.018 19695864 · DOI
  12. [12]Cuzick J. Clavel C. Petry K.U. Meijer C.J. Hoyer H. Ratnam S. Szarewski A. Birembaut P. Kulasingam S. Sasieni P. Overview of the European and North American Studies on HPV Testing in Primary Cervical Cancer Screening Int. J. Cancer 2006 119 1095 1101 10.1002/ijc.21955 16586444 · DOI
  13. [13]van den Akker-van Marle M.E. van Ballegooijen M. van Oortmarssen G.J. Boer R. Habbema J.D. Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies J. Natl. Cancer Inst. 2002 94 193 204 10.1093/jnci/94.3.193 11830609 · DOI
  14. [14]Forman D. de Martel C. Lacey C.J. Soerjomataram I. Lortet-Tieulent J. Bruni L. Vignat J. Ferlay J. Bray F. Plummer M. Global Burden of Human Papillomavirus and Related Diseases Vaccine 2012 30 Suppl. 5 F12 F23 10.1016/j.vaccine.2012.07.055 23199955 · DOI
  15. [15]Asiaf A. Ahmad S.T. Mohammad S.O. Zargar M.A. Review of the Current Knowledge on the Epidemiology, Pathogenesis, and Prevention of Human Papillomavirus Infection Eur. J. Cancer Prev. 2014 23 206 224 10.1097/CEJ.0b013e328364f273 24129107 · DOI
  16. [16]Kessis T.D. Slebos R.J. Nelson W.G. Kastan M.B. Plunkett B.S. Han S.M. Lorincz A.T. Hedrick L. Cho K.R. Human Papillomavirus 16 E6 Expression Disrupts the p53-Mediated Cellular Response to DNA Damage Proc. Natl. Acad. Sci. USA 1993 90 3988 3992 10.1073/pnas.90.9.3988 8387205 PMC46431 · DOI
  17. [17]Huh W.K. Ault K.A. Chelmow D. Davey D.D. Goulart R.A. Garcia F.A. Kinney W.K. Massad L.S. Mayeaux E.J. Saslow D. Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance Obstet. Gynecol. 2015 125 330 337 10.1097/AOG.0000000000000669 25569009 · DOI
  18. [18]Sasagawa T. Maehama T. Ideta K. Irie T. Fujiko Itoh J-HERS Study Group Population-Based Study for Human Papillomavirus (HPV) Infection in Young Women in Japan: A Multicenter Study by the Japanese Human Papillomavirus Disease Education Research Survey Group (J-HERS) J. Med. Virol. 2016 88 324 335 10.1002/jmv.24323 26147986 · DOI
  19. [19]Wang R. Guo X.L. Wisman G.B. Schuuring E. Wang W.F. Zeng Z.Y. Zhu H. Wu S.W. Nationwide Prevalence of Human Papillomavirus Infection and Viral Genotype Distribution in 37 Cities in China BMC Infect. Dis. 2015 15 257 10.1186/s12879-015-0998-5 26142044 PMC4491249 · DOI
  20. [20]Song J.S. Kim E.J. Choi J. Gong G. Sung C.O. Significance of HPV-58 Infection in Women Who are HPV-Positive, Cytology-Negative and Living in a Country with a High Prevalence of HPV-58 Infection PLoS ONE 2013 8 e58678 10.1371/journal.pone.0058678 23505548 PMC3591398 · DOI
  21. [21]Bruni L. Diaz M. Castellsague X. Ferrer E. Bosch F.X. de Sanjose S. Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings J. Infect. Dis. 2010 202 1789 1799 10.1086/657321 21067372 · DOI
  22. [22]Shin H.Y. Lee B. Hwang S.H. Lee D.O. Sung N.Y. Park J.Y. Jun J.K. Evaluation of Satisfaction with Three Different Cervical Cancer Screening Modalities: Clinician-Collected Pap Test Vs. HPV Test by Self-Sampling Vs. HPV Test by Urine Sampling J. Gynecol. Oncol. 2019 30 e76 10.3802/jgo.2019.30.e76 31328458 PMC6658592 · DOI
  23. [23]Kang M. Ha S.Y. Cho H.Y. Chung D.H. Kim N.R. An J. Lee S. Seok J.Y. Jeong J. Comparison of Papanicolaou Smear and Human Papillomavirus (HPV) Test as Cervical Screening Tools: Can we Rely on HPV Test Alone as a Screening Method? An 11-Year Retrospective Experience at a Single Institution J. Pathol. Transl. Med. 2020 54 112 118 10.4132/jptm.2019.11.29 31964113 PMC6986973 · DOI
  24. [24]Kong T.W. Kim M. Kim Y.H. Kim Y.B. Kim J. Kim J.W. Park M.H. Park J.H. Rhee J.H. Lim M.C. High-Risk Human Papillomavirus Testing as a Primary Screening for Cervical Cancer: Position Statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology J. Gynecol. Oncol. 2020 31 e31 10.3802/jgo.2020.31.e31 31789003 PMC6918897 · DOI

Cited by

Sorted by citations

Authors
Kim, M.-S., Lee, E. H., Park, M.-I., Lee, J. S., Kim, K., Roh, M. S., & Lee, H. W.
Affiliations
  • Samsung Changwon Hospital (KR)
  • Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Korea
  • Dong-A University (KR)
Corresponding author
Lee, Hyoun Wook
ORCID
Venue
International Journal of Environmental Research and Public Health
Publisher
MDPI AG
Published
2020-03-06
Volume
17
Issue
5
Pages
1726
ISSN
1660-4601 (ISSN-L)
DOI
10.3390/ijerph17051726
PMC
PMC7084278
OpenAlex
W3009790142
Cited by
7
References
0
Citations by year
2024: 2 · 2023: 1 · 2022: 2 · 2020: 1 · 2019: 1
FWCI
0.72
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
HPV testing, cervical cancer screening, HPV genotyping, HPV prevalence, cervical cytology, sensitivity and specificity, Korean women
MeSH terms
Adult, Aged, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Female, Humans, Mass Screening, Middle Aged, Retrospective Studies, Papillomaviridae, Papillomavirus Infections, Early Detection of Cancer, Republic of Korea

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review